Pre-made Nimacimab benchmark antibody ( Whole mAb, anti-CNR1/CB1 therapeutic antibody, Anti-CANN6/CB-R Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Nimacimab biosimilar, Whole mAb, Anti-CNR1/CB1 Antibody: Anti-CANN6/CB-R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A first-in-class, only-in-class peripheral antagonist antibody to cannabinoid receptor 1 (CB1) for the treatment of fibrotic, metabolic, and inflammatory diseases including nonalcoholic steatohepatitis (NASH) and diabetic kidney disease (DKD).
| Products Name (INN Index) | Pre-Made Nimacimab biosimilar, Whole mAb, Anti-CNR1/CB1 Antibody: Anti-CANN6/CB-R therapeutic antibody |
|---|---|
| INN Name | Nimacimab |
| Target | Cnr1 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Bird Rock Bio |
| Conditions Approved | NA |
| Conditions Active | Diabetic nephropathies,Diabetic gastroparesis,Obesity |
| Conditions Discontinued | Non-alcoholic steatohepatitis,Non-alcoholic fatty liver disease |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CNR1 |
| Package |
